Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Heptares
Biotech
Boehringer pays €25M for option to Sosei’s schizophrenia drug
Boehringer has secured an opportunity to beef up its schizophrenia portfolio courtesy of a €25 million ($27.3 million) deal with Sosei Heptares.
James Waldron
Mar 11, 2024 9:10am
GSK jilts Sosei, axing bowel disease drug amid immunology pivot
Nov 27, 2023 5:00am
AbbVie pays Sosei $40M to form neurological drug discovery pact
Aug 2, 2022 7:00am
Verily links up with Sosei Heptares for GPCR drug discovery
Jan 6, 2022 3:30pm
AbbVie dumps unwanted Sosei neuro pact from Allergan's past
Jan 5, 2021 9:42am
Takeda, Sosei form gastrointestinal disease R&D pact
Aug 5, 2019 9:57am
